活性维生素D体外作为抗TNFα辅助治疗调节银屑病关节炎滑膜成纤维细胞活化模型中人Th17活性
本研究在银屑病关节炎滑膜成纤维细胞与人类记忆CCR6+Th17细胞共培养活化模型中,评估阿达木单抗、司库奇尤单抗及1,25-二羟维生素D3单用或联用的效果。结果显示抗TNFα和/或抗IL-17A显著抑制促炎细胞因子和组织破坏介质,但对IL-22和IFNγ作用有限;在抗TNFα基础上加用1,25(OH)2D3可克服单药抑制Th17细胞因子的局限,并显著增强对IL-6、IL-8和MMPs的抑制,同时促进IL-10产生。作者认为需要临床银屑病关节炎研究来探索该联合方案的额外治疗潜力。
要点
- 抗TNFα和/或抗IL-17A可显著抑制模型中的促炎细胞因子和组织破坏介质。
- 单用抗TNFα或抗IL-17A不能完全抑制Th17与滑膜成纤维细胞间的促炎环路。
- 1,25(OH)2D3联合抗TNFα可增强抑制IL-6、IL-8和MMPs并促进IL-10产生。
核心结论
- 单用TNFα或IL-17A抑制不能完全抑制hmemCCR6+Th17细胞与PsA滑膜成纤维细胞之间的促炎环路,但联合使用对抑制促炎和组织破坏介质显示叠加效应。
- 1,25(OH)2D3与抗TNFα治疗配合在该促炎环路中起互补作用,并显著诱导IL-10。
- 作者认为需要临床PsA研究来探索该联合方案的额外治疗潜力。
研究设计与样本
- 体外研究:将银屑病关节炎活检来源的滑膜成纤维细胞与人类记忆CCR6+Th17细胞共培养,构建PsA滑膜成纤维细胞活化模型。
- 采用流式细胞术分析滑膜成纤维细胞表型,采用Transwell系统评估治疗对滑膜成纤维细胞和hmemCCR6+Th17细胞的作用。
- 干预包括阿达木单抗(抗TNFα)、司库奇尤单抗(抗IL-17A)和/或1,25-二羟维生素D3,单用或联用;细胞因子和基质金属蛋白酶采用ELISA定量。
主要发现
- PsA滑膜成纤维细胞由异质性亚群组成,并与hmemCCR6+Th17细胞构建了促炎反馈环路。
- 抗TNFα和/或抗IL-17A显著抑制PsA滑膜成纤维细胞活化模型中的促炎细胞因子和组织破坏介质,但对IL-22和IFNγ作用有限。
- 在抗TNFα治疗基础上加用1,25(OH)2D3有效克服了单用抗TNFα抑制Th17细胞因子的局限,同时显著增强对IL-6、IL-8和MMPs的抑制。
- 1,25(OH)2D3促进IL-10的产生。
临床怎么用
- 原文结论未据此给出临床推荐。
- 作者认为需要临床PsA研究来探索该联合方案的额外治疗潜力。
局限性
- 原文结论指出需要临床PsA研究来探索该联合方案的额外治疗潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Psoriatic arthritis (PsA) is an IL-23/IL-17/TNF-driven inflammatory arthritis, commonly accompanied by vitamin D deficiency. Here, we investigate the interaction between PsA synovial fibroblasts (SFs) and human memory CCR6+Th17 (hmemCCR6+Th17) cells and evaluate the therapeutic effects of TNFα and/or IL-17A inhibitors, and the adjunctive therapy potential of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). METHODS: SF derived from PsA biopsies were co-cultured with hmemCCR6+Th17 cells to construct a PsA SF activation model. SF phenotypes were analysed by flow cytometry. Treatments included adalimumab (anti-TNFα), secukinumab (anti-IL-17A), and/or 1,25(OH)2D3, applied alone or in combination. A transwell system was used to assess treatment effects on SF and hmemCCR6+Th17 cells. Cytokines and matrix metalloproteinases (MMPs) were quantified by ELISA. RESULTS: PsA SF were composed of heterogeneous subpopulations and constructed a pro-inflammatory feedback loop with hmemCCR6+Th17 cells. Anti-TNFα and/or anti-IL-17A significantly suppressed proinflammatory cytokines and tissue-destructive mediators in the PsA SF activation model, but showed limited effect on IL-22 and IFNγ. Adding 1,25(OH)2D3 to anti-TNFα treatment effectively overcame the limitations of single anti-TNFα in suppressing Th17 cytokines, while significantly enhancing the inhibition of IL-6, IL-8 and MMPs. In addition, 1,25(OH)2D3 promoted the production of IL-10. CONCLUSIONS: TNFα or IL-17A inhibition alone does not completely inhibit the proinflammatory loop between hmemCCR6+Th17 cells and PsA SF, although the combination shows additive effect on suppressing proinflammatory and tissue-destructive mediators. Importantly, 1,25(OH)2D3 plays a complementary role in the treatment of this proinflammatory loop alongside anti-TNFα therapy and significantly induces IL-10. Clinical PsA studies are needed to explore the additional therapeutic potential of this combination.
引用
- He Y, Van Heeswijk B, Mus AMC, et al. Active vitamin D acts in vitro as an adjuvant to anti-TNFα treatment in a psoriatic synovial fibroblast activation model by modulating human Th17 activity. RMD Open. 2025. PMID: 40973226. doi:10.1136/rmdopen-2025-005547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。